Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
McKesson
Johnson and Johnson
Express Scripts
Teva
Accenture
Farmers Insurance
Baxter

Generated: February 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR COMMIT

« Back to Dashboard

Clinical Trials for Commit

Trial ID Title Status Sponsor Phase Summary
NCT00000895 A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A The purpose of this study is to determine if infection with Mycobacterium avium complex (MAC) occurs in other parts of the body before it is found in the blood. This study also evaluates the relationships between the amount of HIV in the blood, immune system functions, and the presence of MAC infection. HIV-positive patients are at risk for MAC infection because their immune systems have been weakened by HIV. It is hoped that aggressive treatment with anti-HIV drugs may improve their immune systems enough to prevent against MAC.
NCT00074737 Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML Completed Eleos, Inc. Phase 2 The principal goal of this clinical trial is to assess the ability of cenersen sodium (EL625) to improve cancer responsiveness to the established AML therapeutic agent Idarubicin used alone or in combination with Cytarabine (Ara-C). Cenersen sodium is a drug that is designed to block the effects of a protein called p53. Laboratory evidence shows that blocking p53 will make many types of cancer, including acute myelogenous leukemia (AML), more sensitive to a variety of established cancer therapeutics while making normal tissues more resistant to the toxic effects of these agents.
NCT00132899 COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial) Completed Schering-Plough Phase 3 The primary objective is to compare the efficacy and safety of infliximab plus methotrexate to infliximab alone for the long-term control of signs and symptoms of Crohn's disease (CD) in patients with symptoms that are persistent enough to require corticosteroid therapy.
NCT00132899 COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial) Completed University of Western Ontario, Canada Phase 3 The primary objective is to compare the efficacy and safety of infliximab plus methotrexate to infliximab alone for the long-term control of signs and symptoms of Crohn's disease (CD) in patients with symptoms that are persistent enough to require corticosteroid therapy.
NCT00174993 Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes Completed Eli Lilly and Company Phase 3 The purpose of this study is to determine whether pioglitazone, once daily (QD), can delay the time to death, heart attack, acute coronary syndrome, heart bypass surgery, stroke, leg bypass surgery or amputation in patients with type 2 diabetes.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Commit

Condition Name

Condition Name for Commit
Intervention Trials
Diabetes Mellitus 12
Depression 2
Crohn's Disease 2
Mycobacterium Avium-intracellulare Infection 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Commit
Intervention Trials
Diabetes Mellitus 13
Diabetes Mellitus, Type 2 3
Depressive Disorder 2
Crohn Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Commit

Trials by Country

Trials by Country for Commit
Location Trials
United States 207
United Kingdom 7
South Africa 6
Mexico 5
Brazil 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Commit
Location Trials
California 11
Florida 10
Texas 10
Pennsylvania 10
Indiana 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Commit

Clinical Trial Phase

Clinical Trial Phase for Commit
Clinical Trial Phase Trials
Phase 4 7
Phase 3 12
Phase 2 6
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Commit
Clinical Trial Phase Trials
Completed 25
Recruiting 6
Not yet recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Commit

Sponsor Name

Sponsor Name for Commit
Sponsor Trials
Takeda 13
National Institute of Mental Health (NIMH) 2
Eli Lilly and Company 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Commit
Sponsor Trials
Other 29
Industry 24
NIH 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Moodys
Accenture
Cipla
Queensland Health
Farmers Insurance
QuintilesIMS
Fish and Richardson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.